(MET) MetLife - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US59156R1086

MET: Insurance, Annuities, Employee Benefits, Asset Management

MetLife, Inc. is a multinational financial services company that offers a wide range of insurance, annuities, and asset management services to individuals, corporations, and institutions worldwide. The company's operations are divided into six distinct segments, including Retirement and Income Solutions, Group Benefits, Asia, Latin America, Europe, the Middle East and Africa, and MetLife Holdings, each catering to specific markets and customer needs. Through these segments, MetLife provides an extensive array of products, including life, dental, disability, and accident insurance, as well as annuities, pension products, and investment solutions.

The company's product portfolio is diverse and comprehensive, featuring various types of insurance coverages, such as group short-and long-term disability, individual disability, pet insurance, and accidental death and dismemberment insurance. Additionally, MetLife offers administrative services-only arrangements to employers, general and separate account contracts, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements. Its pension risk transfer solutions, institutional income annuities, and structured settlements are designed to help institutions and individuals manage their retirement and financial risks. Furthermore, MetLife provides fixed, indexed-linked, and variable annuities, whole and term life insurance, and longevity reinsurance solutions to address the complex needs of its customers.

MetLife's operations are supported by its global presence, with a significant footprint in key markets across Asia, Latin America, Europe, the Middle East, and Africa. The company's commitment to innovation and customer satisfaction has enabled it to maintain a strong position in the global insurance and financial services industry. With a history dating back to 1999, MetLife, Inc. is headquartered in New York, New York, and is listed on the New York Stock Exchange (NYSE) under the ticker symbol MET. The company's common stock is classified under the GICS Sub Industry: Life & Health Insurance, and its ISIN is US59156R1086. For more information, investors and customers can visit the company's website at https://www.metlife.com.

Additional Sources for MET Stock

MET Stock Overview

Market Cap in USD 57,346m
Sector Financial Services
Industry Insurance - Life
GiC Sub-Industry Life & Health Insurance
IPO / Inception 2000-04-05

MET Stock Ratings

Growth 5y 75.8%
Fundamental 35.0%
Dividend 46.6%
Rel. Strength Industry -17.3
Analysts 4.2/5
Fair Price Momentum 93.08 USD
Fair Price DCF 552.46 USD

MET Dividends

Dividend Yield 12m 3.13%
Yield on Cost 5y 6.31%
Annual Growth 5y 3.58%
Payout Consistency 34.6%

MET Growth Ratios

Growth Correlation 3m 2.1%
Growth Correlation 12m 86.6%
Growth Correlation 5y 85.7%
CAGR 5y 15.04%
CAGR/Mean DD 5y 1.34
Sharpe Ratio 12m 1.07
Alpha -3.14
Beta 1.26
Volatility 24.14%
Current Volume 3107.8k
Average Volume 20d 3304.3k
What is the price of MET stocks?
As of January 22, 2025, the stock is trading at USD 86.88 with a total of 3,107,849 shares traded.
Over the past week, the price has changed by +3.64%, over one month by +6.33%, over three months by +3.13% and over the past year by +28.93%.
Is MetLife a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, MetLife is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 34.95 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of MET as of January 2025 is 93.08. This means that MET is currently overvalued and has a potential downside of 7.14%.
Is MET a buy, sell or hold?
MetLife has received a consensus analysts rating of 4.20. Therefor, it is recommend to buy MET.
  • Strong Buy: 7
  • Buy: 5
  • Hold: 2
  • Sell: 1
  • Strong Sell: 0
What are the forecast for MET stock price target?
According to ValueRays Forecast Model, MET MetLife will be worth about 102.3 in January 2026. The stock is currently trading at 86.88. This means that the stock has a potential upside of +17.69%.
Issuer Forecast Upside
Wallstreet Target Price 93.9 8.1%
Analysts Target Price 92.5 6.5%
ValueRay Target Price 102.3 17.7%